

Animalcare Group plc

Interim Report Presentation Six months to 31st December 2012

Developing and Supplying

Veterinary Products for Companion Animals

Business Overview

"A leading supplier of generic veterinary medicines and animal identification products to companion animal veterinary markets in the UK, and selected markets in the EU and other selected markets "

Overview of Results

First six months of the financial year have seen Animalcare return to solid growth

- Revenues +13.0%; Underlying operating profit +20.3%; Cash and cash equivalents +69.1% to £3m
- Strong sales from Licensed Veterinary Medicines
- Resumption of supply of Buprecare ampoules at the end of the period
- Focus on Companion Animal Identification group has stabilised microchip sales and grown other revenues in the group
- Two veterinary medicines launched (Vitofyllin and Buprecare ampoules) and one receiving regulatory approval in the period (Marbocare – RNS 4th October 2012); fourth new product launch expected by end of financial year
- New product development pipeline continues with progress made on registrations close to launch and on Project Sustain platform
- Transition in senior management now complete

Financial Highlights

	6 months ended 31 st December 2012	6 months ended 31 st December 2011	% Change
Revenue	£6.10m	£5.40m	+13.0%
Underlying* EBITDA	£1.57m	£1.32m	+19.4%
Underlying* operating profit	£1.47m	£1.22m	+20.3%
Underlying* profit before tax	£1.48m	£1.22m	+21.5%
Profit for the period	£1.07m	£0.88m	+21.6%
Basic underlying earnings per share	5.8p	4.7p	+23.4%
Interim dividend	1.5p	1.5p	-
Net cash	£2.96m	£1.75m	+69.1%

* Underlying measures are presented before the effect of exceptional costs, amortisation of acquired intangibles and other items.

Product Group Summary

£'000	6 months ended 31 st December 2012	6 months ended 31 st December 2011	% Change
Sales			
Licensed Veterinary Medicines	3,590	2,916	+23.1%
Companion Animal Identification	1,137	1,202	(5.4%)
Animal Welfare	1,376	1,282	+7.3%
Total	6,103	5,400	+13.0%
Gross Profit			
Licensed Veterinary Medicines	2,084	1,617	+28.9%
Companion Animal Identification	807	843	(4.9%)
Animal Welfare	511	483	+14.1%
Total	3,402	2,943	15.6%
Gross Margin %			
Licensed Veterinary Medicines	58.0%	55.5%	+4.5%
Companion Animal Identification	71.0%	70.1%	+1.3%
Animal Welfare	37.1%	37.7%	(1.6%)
Total	55.7%	54.5%	+2.2%

Category Performance

Licensed Veterinary Medicines

- Turnover growth (+23.1%) driven by launches in current or previous financial year; Vitofyllin and Buprecare multi-dose vial
- Gross profit (+28.9%) growth is effect of higher margin new products
- Competition in older licensed medicines reinforces focus on new higher margin products

Companion Animal Identification


- Action taken earlier in 2012 has stabilised the sales of microchips
- Gross margin holding well under competitive pressure due to improved buying position
- Database services have grown 7% as a result of investment in previous financial year in database development

Animal Welfare Products

- Positive action sourcing Infusion Accessories products has underpinned strong performance versus same period last year (+6.7% TO; +12.3% GM), on sales in excess of £650k in the period
- Remaining Animal Welfare Products have held up well in like for like sales

Segmental Analysis

Revenue



Gross Profit

- Licensed Veterinary Medicines
- Companion Animal Identification
- Animal Welfare

Financials – Profit and Loss

	6 months ended 31 st December 2012	6 months ended 31 st December 2011	% Change
	£'000	£'000	
Revenue	6,103	5,400	+13.0%
Gross profit	3,402	2,943	+15.6%
Overheads	(1,934)	(1,723)	(12.2%)
Underlying operating profit	1,468	1,220	+20.3%
Finance income	14	-	-
Underlying profit before tax	1,482	1,220	+21.5%
Exceptional and other items	(139)	(130)	(6.9%)
Profit before tax	1,343	1,090	+23.2%
Taxation	(269)	(207)	(30.0%)
Profit for the period	1,074	883	+23.4%

- Gross margin improved from 54.5% to 55.7% due to higher sales of Licensed Veterinary Medicines
- Overheads increased by £0.2m to £1.9m principally reflecting investment in the senior management team
- Exceptional items include management severance and head office relocation costs
- Half year effective tax rate of 20% based on estimated tax rate for the full financial year; prior year R&D cash tax benefit of £0.2m in first half of which 50% reflected in P&L

Financials – Balance Sheet and Cash Flow

Balance sheet

Cash flow

£'000	6 months ended 31 st December 2012	6 months ended 31 st December 2011	£'000	6 months ended 31 st December 2012	6 months ended 31 st December 2011
Intangible Assets	14,344	14,554	Operating cash flows	1,534	1,255
Plant and equipment	98	59	Movement in working capital	(232)	168
Non-current assets	14,442	14,613	Taxation	35	(120)
Net working capital	1,633	1,293	Net cash flow from	1,337	1,303
Cash	2,956	1,750	operating activities		
Current tax	(464)	(407)	Net capital expenditure	(100)	(189)
Deferred tax	(180)	(65)	Interest received	12	-
Deferred income	(1,032)	(1,049)	Financing activities	(598)	(543)
Net assets	17,355	16,135	Net cash generated	651	571

- Net working capital £0.2m higher than 30th June 2012 and £0.3m higher than 31st December 2011 – reflecting growth in sales towards the period end
- Strong cash position at £2.96 million expect to reduce in H2 following business relocation and NPD spend.
- Net cash flow from operating activities comparable to FY11 with increase in working capital offset by a prior year research and development tax credit of £0.2m
- Capex lower than expected and prior period but this is a phasing issue; NPD anticipated to be in line with the full year market expectations
- Final FY12 dividend maintained at 3.0p per share

2012/13 Outlook

Second half trading ahead of last year and in line with expectations

Veterinary Medicines

- New products launched in FY12 and FY13 still not at maturity
- On target to launch four veterinary medicines by year end

Companion Animal Identification

- Further progress with microchip sales expected; associated high margin database services anticipated to continue strongly
- Compulsory microchipping set to have positive impact on microchip and database sales

Animal Welfare Products

 Infusion Accessories range expected to continue positive performance, with rest of group selling in line with management expectations

NPD pipeline

- Good progress on final stages of Stone 2 registration
- Projects further up the development process close to entering registration procedure

Animalcare Strategy

Animalcare has built core product development and regulatory skills, credibility and EU partner network over last 10 years which has delivered strong growth

However,

- · the market for generic veterinary licensed medicines increasingly crowded
- simple product differentiation no longer enough to sustain the planned growth of the business
- Intellectual Property protectable differentiation will provide the medium-term motor for growth

Therefore Animalcare's strategy has evolved to sustain growth by

- continuing new product development of differentiated generic medicines at the current pace
 - better penetration in current markets
 - increased geographic cover particularly within the EU and potentially North America
- selective strengthening of the UK Companion Animal Identification range of goods and services
- removing resources from and allow the decline of non-core product groups
- accelerate Project Sustain
 - initially in enhanced generics
 - then in novel veterinary medicines

Delivering the Strategy

- Iain Menneer, CEO January 2013
 - Joined Animalcare Ltd in December 2003
 - Product Manager, Licensed Pharmaceuticals
 - Business Development Manager (Benazecare, Buprecare, Anivac, Sedastart/stop)
 - Director of Marketing
 - Managing Director, Animalcare Ltd in March 2012
- Strengthened senior management team in place
 - Finance, Chris Brewster CFO
 - KPMG rising to Senior Manager in the audit team in Leeds, Findus Group Accounting Manager
 - Sales, Tim Rayner
 - 20 years in animal health industry, former Key Account Manager Pfizer Animal Health
 - Marketing, Rachel Crowe
 - 10 years in animal health industry, sales and marketing roles in top 10 animal health companies
 - Regulatory Affairs, Torben Orskov
 - Veterinary surgeon with 10 years experience in practice and 6 years at Animalcare
- Director of Business Development recruitment underway

New Product Development Pipeline

Project	Sector	Expected launch*	Target Markets	Years to Maturity	
Differentiated and undifferentiated generics					
Stone 1	Livestock	2013	Limited EU	5	
Stone 2	Companion Animal	2013	Limited EU	3	
Poppy II	Companion Animal	2013	Selected EU	2	
Raleigh	Companion Animal	2014	EU and others	3	
Amigo	Companion Animal	2014	Selected EU	3	
Calm	Companion Animal	2014	Selected EU	3	
Isle	Companion Animal	2015	EU and others	3	
Beat	Companion Animal	2015	EU and others	3	
Sustain Projects					
Archipelago	Companion Animal	2016	EU and others	2	
Phoenix	Companion Animal	2016	Selected EU	3	
Sally	Companion Animal	2017	EU and others	2	
Cardinal	Companion Animal and Livestock	2018	EU and others	-	

*All dates are calendar year

• At maturity UK sales are expected to be between £5 to £7 million per annum

Animalcare Group plc



Developing and Supplying

Veterinary Products for Companion Animals